The content on this site is intended for healthcare professionals only
Dr Ana Baramidze talks to ecancer about her EMPOWER-Lung 1 phase 3 trial.
It investigated cemiplimab, a PD-1 inhibitor, as a first-line treatment for advanced non-small-cell lung cancer (NSCLC) in patients with PD-L1 expression of at least 50%.
The study showed that cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy, with fewer severe adverse events.
These results suggest cemiplimab could offer a new treatment option for this patient population.
WCLC 2025: Latest in EGFR positive NSCLC
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
